Emerging utility of once-weekly exenatide in patients with type 2 diabetes

被引：3

作者：

Goud, Aditya ^{[1
]}

Zhong, Jixin ^{[1
]}

Rajagopalan, Sanjay ^{[1
]}

机构：

[1] Univ Maryland, Dept Med, Div Cardiovasc Med, Baltimore, MD 21201 USA

来源：

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2015年 / 8卷

关键词：

incretin; glucagon-like peptide; hyperglycemia; glucose lowering;

D O I：

10.2147/DMSO.S69354

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.

引用

页码：505 / 512

页数：8

共 50 条

[1] Once-weekly exenatide in type 2 diabetes
Dinesh M. Parmar
Shilpa P. Jadav
[J]. International Journal of Diabetes in Developing Countries, 2011, 31 : 121 - 122
[2] Once-weekly exenatide in type 2 diabetes
Parmar, Dinesh M.
Jadav, Shilpa P.
[J]. INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2011, 31 (02) : 121 - 122
[3] Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane, William, V
Bishai, Raafat
Geller, David
Shehadeh, Naim
Al-Abdulrazzaq, Dalia
Manica Vazquez, Evelina
Karoly, Eva
Troja, Tunde
Doehring, Orlando
Carter, Debra
Monyak, John
Sjostrom, C. David
[J]. DIABETES CARE, 2022, 45 (08) : 1833 - 1840
[4] Once-weekly exenatide as a treatment for Type 2 diabetes
Schauerhamer, Marisa B.
Gurgle, Holly
McAdam-Marx, Carrie
[J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (06) : 611 - 626
[5] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Holman, Rury R.
Bethel, M. Angelyn
Mentz, Robert J.
Thompson, Vivian P.
Lokhnygina, Yuliya
Buse, John B.
Chan, Juliana C.
Choi, Jasmine
Gustavson, Stephanie M.
Iqbal, Nayyar
Maggioni, Aldo P.
Marso, Steven P.
Ohman, Peter
Pagidipati, Neha J.
Poulter, Neil
Ramachandran, Ambady
Zinman, Bernard
Hernandez, Adrian F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1228 - 1239
[6] Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes Reply
Holman, Rury R.
Bethel, M. Angelyn
Hernandez, Adrian F.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2502 - 2502
[7] Exenatide extended-release: A once-weekly option for patients with type 2 diabetes
Anderson, Zachary L.
Clements, Jennifer N.
[J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (06): : 44 - 46
[8] Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
Ryan, Gina J.
Moniri, Nader H.
Smiley, Dawn D.
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (13) : 1123 - 1131
[9] Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
Deng, Wuquan
Qiu, Sheng
Yang, Gangyi
Chen, Bing
[J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1153 - 1162
[10] Exenatide once weekly in type 2 diabetes
Scheen, Andre J.
[J]. LANCET, 2008, 372 (9645): : 1197 - 1198

← 1 2 3 4 5 →